- Home
- LRMR vs CDXS Comparison
LRMR vs CDXS Comparison
Compare LRMR & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- CDXS
- Stock Information
- Founded
- LRMR N/A
- CDXS 2002
- Country
- LRMR United States
- CDXS United States
- Employees
- LRMR N/A
- CDXS N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- LRMR Health Care
- CDXS Industrials
- Exchange
- LRMR Nasdaq
- CDXS Nasdaq
- Market Cap
- LRMR 426.9M
- CDXS 361.3M
- IPO Year
- LRMR N/A
- CDXS 2010
- Fundamental
- Price
- LRMR $3.19
- CDXS $4.18
- Analyst Decision
- LRMR Strong Buy
- CDXS Buy
- Analyst Count
- LRMR 9
- CDXS 2
- Target Price
- LRMR $19.44
- CDXS $11.00
- AVG Volume (30 Days)
- LRMR 639.4K
- CDXS 566.1K
- Earning Date
- LRMR 03-13-2025
- CDXS 02-27-2025
- Dividend Yield
- LRMR N/A
- CDXS N/A
- EPS Growth
- LRMR N/A
- CDXS N/A
- EPS
- LRMR N/A
- CDXS N/A
- Revenue
- LRMR N/A
- CDXS $64,446,000.00
- Revenue This Year
- LRMR N/A
- CDXS N/A
- Revenue Next Year
- LRMR N/A
- CDXS $2.02
- P/E Ratio
- LRMR N/A
- CDXS N/A
- Revenue Growth
- LRMR N/A
- CDXS N/A
- 52 Week Low
- LRMR $3.01
- CDXS $2.56
- 52 Week High
- LRMR $12.91
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- LRMR 37.56
- CDXS 41.30
- Support Level
- LRMR $3.06
- CDXS $4.14
- Resistance Level
- LRMR $3.52
- CDXS $4.41
- Average True Range (ATR)
- LRMR 0.22
- CDXS 0.22
- MACD
- LRMR 0.02
- CDXS 0.01
- Stochastic Oscillator
- LRMR 15.66
- CDXS 38.89
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.